RETHINC
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 535 symptomatic tobacco-exposed adults with preserved spirometry, indacaterol-glycopyrronium for 12 weeks did not improve respiratory symptoms (SGRQ ≥4-point response) compared with placebo.
N
535
Disegno
Multicentre RCT
Esito
≥4-point improvement in SGRQ at 12 weeks
Rilevanza
3
Risultato56.4% vs 59.0% (p=0.65).
Han MK, et al. N Engl J Med. 2022;387(13):1173-1184. 10.1056/NEJMoa2204752
Discussione e critica
Spirometry is essential before initiating COPD therapy; bronchodilators do not help symptomatic smokers without airflow obstruction.